HALO Halozyme Therapeutics, Inc.
$96.50
Halozyme Therapeutics, Inc. (HALO) Earnings News
Earnings press releases, previews and reviews for Halozyme Therapeutics, Inc. (HALO), newest first. Our most recent is review: Halozyme Posts Record Royalties, a Third Guidance Raise and a European Win Against Merck, but the Raise Is Smaller and Growth Is Cooling.
Thursday
November 5, 2026
8:54 PM ET
Halozyme Posts Record Royalties, a Third Guidance Raise and a European Win Against Merck, but the Raise Is Smaller and Growth Is Cooling
Earnings Whispers · Review
Thursday
November 5, 2026
4:05 PM ET
HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Wednesday
October 28, 2026
7:58 PM ET
Halozyme Faces a Higher Bar as Royalty Cadence Tests Its Rally
Earnings Whispers · Preview
Thursday
October 22, 2026
8:30 AM ET
Halozyme to Report Third Quarter 2026 Financial and Operating Results
Thursday
August 6, 2026
4:01 PM ET
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Thursday
July 23, 2026
8:30 AM ET
Halozyme to Report Second Quarter 2026 Financial and Operating Results